Loading organizations...
§ Private Profile · Mont-saint-guibert, Brabant Wallon, Belgium
Develops machine learning analytical tools to optimize clinical development for biopharmaceutical companies, focusing on patient variability.
Cognivia develops predictive, machine learning-based analytical tools designed to optimize the clinical development of medicines for global biopharmaceutical companies and research institutions. The organization provides software solutions that allow medical researchers to quantify and understand patient variability during their clinical trials. Originally operating under the corporate name Tools4Patient, the enterprise officially rebranded to its current identity in 2021, marking exactly eight years since its initial corporate inception. The company recently secured additional financial backing from lead investor Vesalius Biocapital IV in 2024 to further scale its core analytical operations and expand its executive board, which currently includes Chief Operating Officer Chantal Gosselin. The firm continues to gain broader industry recognition, with its chief executive recently named among the top healthcare technology chief executives of 2025. Cognivia was originally founded in 2013 by Dr. Dominique Demolle.
Cognivia has raised $21.0M across 2 funding rounds.
Cognivia has raised $21.0M in total across 2 funding rounds.
Cognivia has raised $21.0M in total across 2 funding rounds.
Cognivia's investors include SFPI-FPIM, Vesalius Biocapital IV, We Venture Capital, Jean-Pierre Delwart, Jean Stephenne, Innovation Fund, Sambrinvest.
Cognivia has raised $21.0M across 2 funding rounds. Most recently, it raised $16.5M Other Equity in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 18, 2024 | $16.5M Venture Round | — | Sfpi Fpim, Vesalius Biocapital IV, WE Venture Capital | Announced |
| May 17, 2019 | $4.5M Series B | — | Jean Pierre Delwart, Jean Stephenne, Innovation Fund, Sambrinvest | Announced |